The Virtual Hospital - a Clinical Trial

Summary

Introduction:

With the rapid development in technology telemedicine has become a tool with the potential to improve and optimize the treatment of different diseases and to make diagnostics, treatment and counseling possible over shorter or longer distances.

Home based telemedicine is a new method that leads to a series of important questions that needs to be answered. This study is designed to answer questions concerning patient safety in telehomecare, the patients´ quality of life, efficiency and a cost benefit analysis of implementing this technology.

This study is about patients with chronic obstructive pulmonary disease (COPD) who are admitted to the hospital with an acute exacerbation. Approximately 24 hours after admission half of the patients are randomized to be admitted to their own home supported by telemedical equipment while the other half remain admitted at the hospital (typically between 5-7 days).

Primary Aim:

To investigate if telemedical surveillance and treatment in the recovery period of an acute exacerbation is just as safe as conventional admission of patients with COPD measured on treatment failure.

Secondary Aims:

To evaluate if telemedical surveillance and treatment in the recovery period of an acute exacerbation compared to conventional treatment of COPD:

1. Is comparable in reestablishing Forced Expiratory Volume in 1 second (FEV1).
2. Demands the same number of treatment days/time before discharge/cessation of telemedical surveillance.
3. Is comparable in quality of life in the two groups of treated patients.
4. Have comparable adverse event profiles.
5. leads to a lower total cost in health services (health economical analysis)
6. Is possible to do for the patients (drop-outs because of the technical equipment or the patient does not know how to use the equipment.)

7 Is better seen from the physician's perspective when it comes to:

1. The virtual patient contact / communication
2. Technology
3. The work process compared to the conventional work process
4. Time spent with the patient
5. Usability
6. Improvement potentials ("the doctors view")

8\. The equipment is satisfactory for the patient to use

Method

For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients´ health condition (lung function, oxygen saturation, pulse etc.) 175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participates in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.

Conditions

• Chronic Obstructive Pulmonary Disease
• Telemedicine

Interventions

OTHER

Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital

For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.

Sponsors & Collaborators

• TRYG Foundation

  collaborator OTHER

• The TOYOTA Foundation

  collaborator UNKNOWN

• Sygekassernes Helsefond

  collaborator OTHER

• Lykfeldt legat

  collaborator UNKNOWN

• Frederiksberg Fonden

  collaborator UNKNOWN

• Danmarks Lungeforening

  collaborator OTHER

• Frederiksberg University Hospital

  lead OTHER

Principal Investigators

• Klaus V Phanareth, ass.professor · Frederiksberg Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

45 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-06-30

Primary Completion

2013-06-30

Completion

2013-06-30

Countries

• Denmark

Study Locations